Tech Company M&A Transactions
Arresto Biosciences Acquisition
Operating out of Palo Alto, Arresto Biosciences was acquired by Gilead Sciences. The transaction price was $225 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/20/2010
Transaction Type
M&A
Amount
$225,000,000
M&A Terms
Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3183 Porter Dr.
Palo Alto, CA 94304
USA
Palo Alto, CA 94304
USA
Phone
Website
Email Address
Not Recorded
Overview
Arresto BiosciencesTM is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Vlasselaer
Vice President
Dung Thai
VP - R & D
Victoria Smith
Browse more venture capital transactions:
Prev: 12/20/2010: Lux Biosciences venture capital transaction
Next: 12/20/2010: Capricor Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs